[P3-166]: NEUROTRANSMITTER-SPECIFIC METABOLISM IS RELATED TO SEVERITY OF PATHOLOGY AND SYMPTOM EXPRESSION IN ALZHEIMER's DISEASE

Three of the four approved treatments for Alzheimer's disease (AD) are cholinesterase inhibitors, which reduce the breakdown of acetylcholine in the brains of AD patients. However, acetylcholine is only one of a group of important small molecule neurotransmitters that are crucial to the healthy functioning of the brain and the role of other neurotransmitters in AD pathogenesis is poorly understood. In this study, we measured the abundance of a...